Alzheimer’s disease (AD) is a neurodegenerative disorder that is characterized by progressive loss of memory, confusion, inability of speech and decline in the cognitive behavior. It is considered one of the most common forms of dementia. Clinical studies and preclinical data in the last decade proved that AD and Diabetes mellitus share a pathophysiological pathway, indicating that insulin resistance, oxidative stress and inflammatory response would increase the risks of developing AD in diabetic patients. This review presents briefly the etiology of AD and Diabetes, discusses the possible theories about the interplaying risk factors and the mechanism of action of anti-diabetic medications recommended for the treatment of AD. It is concluded that antidiabetics have good potential to improve dementia, especially in earlier AD stages. However, many of the underlying intricate molecular pathways are still unclear and thus thorough future research is required.
Pardeshi, R., et al. (2017) Insulin Signaling: An Opportunistic Target to Minify the Risk of Alzheimer’s Disease. Psychoneuroendocrinology, 83, 159-171. https://doi.org/10.1016/j.psyneuen.2017.05.004
de la Monte, S.M. and Wands, J.R. (2008) Alzheimer’s Disease Is Type 3 Diabetes-Evidence Reviewed. Journal of Diabetes Science and Technology, 2, 1101-1113. https://doi.org/10.1177/193229680800200619
De Felice, F.G., Lourenco, M.V. and Ferreira, S.T. (2014) How Does Brain Insulin Resistance Develop in Alzheimer’s Disease? Alzheimer’s & Dementia, 10, S26-32. https://doi.org/10.1016/j.jalz.2013.12.004
LaFerla, F.M., Green, K.N. and Oddo, S. (2007) Intracellular Amyloid-Beta in Alzheimer’s Disease. Nature Reviews. Neuroscience, 8, 499-509. https://doi.org/10.1038/nrn2168
Hardy, J. and Selkoe, D.J. (2002) The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics. Science, 297, 353-356. https://doi.org/10.1126/science.1072994
Akter, K., et al. (2011) Diabetes Mellitus and Alzheimer’s Disease: Shared Pathology and Treatment? British Journal of Clinical Pharmacology, 71, 365-376. https://doi.org/10.1111/j.1365-2125.2010.03830.x
Gasparini, L., et al. (2002) Does Insulin Dysfunction Play a Role in Alzheimer’s Disease? Trends in Pharmacological Sciences, 23, 288-293. https://doi.org/10.1016/S0165-6147(02)02037-0
Bekris, L.M., et al. (2010) Genetics of Alzheimer Disease. Journal of Geriatric Psychiatry and Neurology, 23, 213-227. https://doi.org/10.1177/0891988710383571
Goldman, J.S., et al. (2011) Genetic Counseling and Testing for Alzheimer Disease: Joint Practice Guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genetics in Medicine, 13, 597-605. https://doi.org/10.1097/GIM.0b013e31821d69b8
Francis, P.T., et al. (1999) The Cholinergic Hypothesis of Alzheimer’s Disease: A Review of Progress. Journal of Neurology, Neurosurgery, and Psychiatry, 66, 137-147. https://doi.org/10.1136/jnnp.66.2.137
Forstl, H. and Kurz, A. (1999) Clinical Features of Alzheimer’s Disease. European Archives of Psychiatry and Clinical Neuroscience, 249, 288-290. https://doi.org/10.1007/s004060050101
Association, A.S. (2017) Alzheimer’s Association Report: 2017 Alzheimer’s Disease Facts and Figures. Alzheimer’s & Dementia, 13, 325-373. https://doi.org/10.1016/j.jalz.2017.02.001
Hebert, L.E., et al. (2010) Change in Risk of Alzheimer Disease over Time. Neurology, 75, 786-791. https://doi.org/10.1212/WNL.0b013e3181f0754f
Baglietto-Vargas, D., et al. (2016) Diabetes and Alzheimer’s Disease Crosstalk. Neuroscience & Biobehavioral Reviews, 64, 272-287. https://doi.org/10.1016/j.neubiorev.2016.03.005
Ma, H.R., et al. (2018) Cerebral Glucose Metabolic Prediction from Amnestic Mild Cognitive Impairment to Alzheimer’s Dementia: A Meta-Analysis. Translational Neurodegeneration, 7, 9. https://doi.org/10.1186/s40035-018-0114-z
Baumgart, M., Snyder, H.M., Carrillo, M.C., Fazio, S., Kim, H. and Johns, H. (2015) Summary of the Evidence on Modifiable Risk Factors for Cognitive Decline and Dementia: A Population-Based Perspective. Alzheimer’s & Dementia, 11, 718-726. https://doi.org/10.1016/j.jalz.2015.05.016
Sando, S.B., et al. (2008) Risk-Reducing Effect of Education in Alzheimer’s Disease. International Journal of Geriatric Psychiatry, 23, 1156-1162. https://doi.org/10.1002/gps.2043
Farina, N., Rusted, J. and Tabet, N. (2014) The Effect of Exercise Interventions on Cognitive Outcome in Alzheimer’s Disease: A Systematic Review. International Psychogeriatrics, 26, 9-18.
Onieva-Zafra, M. D., Hernández-Garcia, L., Gonzalez-del-Valle, M.T., Parra-Fernández, M.L. and Fernandez-Martinez, E. (2018) Music Intervention with Reminiscence Therapy and Reality Orientation for Elderly People with Alzheimer Disease Living in a Nursing Home: A Pilot Study. Holistic Nursing Practice, 32, 43-50. https://doi.org/10.1097/HNP.0000000000000247
Cacabelos, R. (2007) Donepezil in Alzheimer’s Disease: From Conventional Trials to Pharmacogenetics. Neuropsychiatric Disease and Treatment, 3, 303-333.
Olin, J. and Schneider, L. (2002) Galantamine for Alzheimer’s Disease. The Cochrane Database of Systematic Reviews, Article ID: CD001747.
Loy, C. and Schneider, L. (2006) Galantamine for Alzheimer’s Disease and Mild Cognitive Impairment. The Cochrane Database of Systematic Reviews, Article ID: CD001747. https://doi.org/10.1002/14651858.CD001747.pub3
Cacabelos, R., Takeda, M. and Winblad, B. (1999) The Glutamatergic System and Neurodegeneration in Dementia: Preventive Strategies in Alzheimer’s Disease. International Journal of Geriatric Psychiatry, 14, 3-47. https://doi.org/10.1002/(SICI)1099-1166(199901)14:1 3.0.CO;2-7
Furiya, Y., Tomiyama, T., Izumi, T., Ohba, N. and Ueno, S. (2018) Rivastigmine Improves Appetite by Increasing the Plasma Acyl/Des-Acyl Ghrelin Ratio and Cortisol in Alzheimer Disease. Dementia and Geriatric Cognitive Disorders Extra, 8, 77-84. https://doi.org/10.1159/000487358
Eric, S., Benjamin, T.M., Enrique, J.R., et al. (2005) Impaired Insulin and Insulin-Like Growth Factor Expression and Signaling Mechanisms in Alzheimer’s Disease-Is This Type 3 Diabetes? Journal of Alzheimer's Disease, 7, 63-80. https://doi.org/10.3233/JAD-2005-7107
Kroner, Z. (2009) The Relationship between Alzheimer’s Disease and Diabetes: Type 3 Diabetes? Alternative Medicine Review, 14, 373-379.
Gloyn, A.L. and Drucker, D.J. (2018) Precision Medicine in the Management of Type 2 Diabetes. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/S2213-8587(18)30052-4
Toledano, Y., Hadar, E. and Hod, M. (2018) Pharmacotherapy for Hyperglycemia in Pregnancy-The New Insulins. Diabetes Research and Clinical Practice. https://doi.org/10.1016/j.diabres.2018.04.035
Simó, R., Ciudin, A., Simó-Servat, O. and Hernández, C. (2017) Cognitive Impairment and Dementia: A New Emerging Complication of Type 2 Diabetes-The Diabetologist’s Perspective. Acta Diabetologica, 54, 417-424. https://doi.org/10.1007/s00592-017-0970-5
Markowicz-Piasecka, M., Sikora, J., Szydłowska, A., Skupień, A., Mikiciuk-Olasik, E. and Huttunen, K.M. (2017) Metformin—A Future Therapy for Neurodegenerative Diseases: Theme: Drug Discovery, Development and Delivery in Alzheimer’s Disease Guest Editor: Davide Brambilla. Pharmaceutical Research, 34, 2614-2627. https://doi.org/10.1007/s11095-017-2199-y
Leloup, C., Allard, C., Carneiro, L., Fioramonti, X., Collins, S. and Pénicaud, L. (2016) Glucose and Hypothalamic Astrocytes: More than a Fueling Role? Neuroscience, 323, 110-120. https://doi.org/10.1016/j.neuroscience.2015.06.007
Biessels, G.J., Staekenborg, S., Brunner, E., Brayne, C. and Scheltens, P. (2006) Risk of Dementia in Diabetes Mellitus: A Systematic Review. The Lancet Neurology, 5, 64-74. https://doi.org/10.1016/S1474-4422(05)70284-2
Zhang, J., Chen, C.X. and Hua, S.Z., et al. (2017) An Updated Meta-Analysis of Cohort Studies: Diabetes and Risk of Alzheimer's Disease. Diabetes Research and Clinical Practice, 124, 41-47. https://doi.org/10.1016/j.diabres.2016.10.024
Peila, R., Rodriguez, B.L. and Launer, L.J. (2002) Type 2 Diabetes, APOE Gene, and the Risk for Dementia and Related Pathologies: The Honolulu-Asia Aging Study. Diabetes, 51, 1256-1262. https://doi.org/10.2337/diabetes.51.4.1256
de la Monte, S.M. (2014) Type 3 Diabetes Is Sporadic Alzheimer’s Disease: Mini-Review. European Neuropsychopharmacology, 24, 1954-1960. https://doi.org/10.1016/j.euroneuro.2014.06.008
Schulingkamp, R.J., Pagano, T.C., Hung, D. and Raffa, R.B. (2000) Insulin Receptors and Insulin Action in the Brain: Review and Clinical Implications. Neuroscience & Biobehavioral Reviews, 24, 855-872. https://doi.org/10.1016/S0149-7634(00)00040-3
Butterfield, D.A., Domenico, F.D. and Barone, E. (2014) Elevated Risk of Type 2 Diabetes for Development of Alzheimer Disease: A Key Role for Oxidative Stress in Brain. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1842, 1693-1706. https://doi.org/10.1016/j.bbadis.2014.06.010
Suzanne, C., et al. (1993) Effects of Hyperglycemia on Memory and Hormone Levels in Dementia of the Alzheimer Type: A Longitudinal Study. Behavioral Neuroscience, 107, 926-940. https://doi.org/10.1037/0735-7044.107.6.926
Frölich, L., et al. (1998) Brain Insulin and Insulin Receptors in Aging and Sporadic Alzheimer’s Disease. Journal of Neural Transmission, 105, 423-438. https://doi.org/10.1007/s007020050068
de la Monte, S.M. and Tong, M. (2014) Brain Metabolic Dysfunction at the Core of Alzheimer’s Disease. Biochemical Pharmacology, 88, 548-549. https://doi.org/10.1016/j.bcp.2013.12.012
de la Monte, S.M. (2009) Insulin Resistance and Alzheimer’s Disease. BMB Reports, 42, 475-481. https://doi.org/10.5483/BMBRep.2009.42.8.475
Kandimalla, R., Thirumala, V. and Reddy, P.H. (2017) Is Alzheimer’s Disease a Type 3 Diabetes? A Critical Appraisal. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1863, 1078-1089. https://doi.org/10.1016/j.bbadis.2016.08.018
Akiyama, H., et al. (2000) Inflammation and Alzheimer’s Disease. Neurobiology of Aging, 21, 383-421. https://doi.org/10.1016/S0197-4580(00)00124-X
Rogers, J. and Shen, Y. (2000) A Perspective on Inflammation in Alzheimer’s Disease. Annals of the New York Academy of Sciences, 924, 132-135. https://doi.org/10.1111/j.1749-6632.2000.tb05571.x
Mittal, K. and Katare, D.P. (2016) Shared Links between Type 2 Diabetes Mellitus and Alzheimer’s Disease: A Review. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 10, S144-S149. https://doi.org/10.1016/j.dsx.2016.01.021
de la Monte, S.M., Ming, T., Nataniel, L.-C., Michael P.J. and Wands, J.R. (2006) Therapeutic Rescue of Neurodegeneration in Experimental Type 3 Diabetes: Relevance to Alzheimer’s Disease. Journal of Alzheimer’s Disease, 10, 89-109. https://doi.org/10.3233/JAD-2006-10113
Akhtar, M.W., et al. (2016) Elevated Glucose and Oligomeric β-Amyloid Disrupt Synapses via a Common Pathway of Aberrant Protein S-Nitrosylation. Nature Communications, 7, Article ID: 10242. https://doi.org/10.1038/ncomms10242
Clodfelder-Miller, B.J., Zmijewska, A.A., Johnson, G.V.W. and Jope, R.S. (2006) Tau Is Hyperphosphorylated at Multiple Sites in Mouse Brain in Vivo after Streptozotocin-Induced Insulin Deficiency. Diabetes, 55, 3320-3325. https://doi.org/10.2337/db06-0485
de la Monte, S.M. (2012) Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimer’s Disease. Current Alzheimer Research, 9, 35-66. https://doi.org/10.2174/156720512799015037
Spires-Jones, T.L., Stoothoff, W.H., de Calignon, A., Jones, P.B. and Hyman, B.T. (2009) Tau Pathophysiology in Neurodegeneration: A Tangled Issue. Trends in Neurosciences, 32, 150-159. https://doi.org/10.1016/j.tins.2008.11.007
Abbondante, S., Baglietto-Vargas, D., Rodriguez-Ortiz, C.J., Estrada-Hernandez, T., Medeiros, R. and LaFerla, F.M. (2014) Genetic Ablation of Tau Mitigates Cognitive Impairment Induced by Type 1 Diabetes. American Journal of Pathology, 184, 819-826. https://doi.org/10.1016/j.ajpath.2013.11.021
Thakur, A., Wang, X.L., Siedlak, S.L., Perry, G., Smith, M.A. and Zhu, X.W. (2007) C-Jun Phosphorylation in Alzheimer Disease. Journal of Neuroscience Research, 85, 1668-1673. https://doi.org/10.1002/jnr.21298
Goodpaster, B.H., et al. (2005) Obesity, Regional Body Fat Distribution, and the Metabolic Syndrome in Older Men and Women. Archives of Internal Medicine, 165, 777-783. https://doi.org/10.1001/archinte.165.7.777
Campbell, I.W. (2000) Antidiabetic Drugs Present and Future: Will Improving Insulin Resistance Benefit Cardiovascular Risk in Type 2 Diabetes Mellitus? Drugs, 60, 1017-1028. https://doi.org/10.2165/00003495-200060050-00004
Gustafson, D., et al. (2003) An 18-Year Follow-Up of Overweight and Risk of Alzheimer Disease. Archives of Internal Medicine, 163, 1524-1528. https://doi.org/10.1001/archinte.163.13.1524
Naderali, E.K., Ratcliffe, S.H. and Dale, M.C. (2009) Obesity and Alzheimer’s Disease: A Link between Body Weight and Cognitive Function in Old Age. American Journal of Alzheimer’s Disease & Other Dementias, 24, 445-449. https://doi.org/10.1177/1533317509348208
Femminella, G.D. and Bencivenga, L., et al. (2017) Antidiabetic Drugs in Alzheimer’s Disease: Mechanisms of Action and Future Perspectives. Journal of Diabetes Research, 2017, Article ID: 7420796.
Shingo, A.S., Kanabayashi, T., Kito, S. and Murase, T. (2012) Intracerebroventricular Administration of an Insulin Analogue Recovers STZ-Induced Cognitive Decline in Rats. Behavioural Brain Research, 241, 105-111.
Freiherr, J., et al. (2013) Intranasal Insulin as a Treatment for Alzheimer’s Disease: A Review of Basic Research and Clinical Evidence. CNS Drugs, 27, 505-514. https://doi.org/10.1007/s40263-013-0076-8
Landreth, G. (2007) Therapeutic Use of Agonists of the Nuclear Receptor PPARγ in Alzheimer’s Disease. Current Alzheimer Research, 4, 159-164. https://doi.org/10.2174/156720507780362092
Wang, L., Liu, W., Fan, Y., Liu, T.T. and Yu, C.J. (2017) Effect of Rosiglitazone on Amyloid Precursor Protein Processing and Aβ Clearance in Streptozotocin-Induced Rat Model of Alzheimer’s Disease. Iranian Journal of Basic Medical Sciences, 20, 474-480.
Pancani, T., et al. (2009) Distinct Modulation of Voltage-Gated and Ligand-Gated Ca2+ Currents by PPAR-γ Agonists in Cultured Hippocampal Neurons. Journal of Neurochemistry, 109, 1800-1811. https://doi.org/10.1111/j.1471-4159.2009.06107.x
Harrington, C., et al. (2011) Rosiglitazone Does not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimer’s Disease: Two Phase 3 Studies. Current Alzheimer Research, 8, 592-606. https://doi.org/10.2174/156720511796391935
Cheng, H.W., Shang, Y.P., Jiang, L., Shi, T.-L. and Wang, L. (2016) The Peroxisome Proliferators Activated Receptor-Gamma Agonists as Therapeutics for the Treatment of Alzheimer’s Disease and Mild-to-Moderate Alzheimer’s Disease: A Meta-Analysis. International Journal of Neuroscience, 126, 299-307. https://doi.org/10.3109/00207454.2015.1015722
Alp, H., et al. (2012) Protective Effects of Beta Glucan and Gliclazide on Brain Tissue and Sciatic Nerve of Diabetic Rats Induced by Streptozosin. Experimental Diabetes Research, 2012, Article ID: 230342.
Irons, B.K. and Minze, M.G. (2014) Drug Treatment of Type 2 Diabetes Mellitus in Patients for whom Metformin Is Contraindicated. Diabetes, Metabolic Syndrome and Obesity, 7, 15-24. https://doi.org/10.2147/DMSO.S38753
Li, S.-N., Wang, X., Zeng, Q.T., Feng, Y.B., et al. (2009) Metformin Inhibits Nuclear Factor κB Activation and Decreases Serum High-Sensitivity C-Reactive Protein Level in Experimental Atherogenesis of Rabbits. Heart Vessels, 24, 446-453. https://doi.org/10.1007/s00380-008-1137-7
Rena, G., Pearson, E.R. and Sakamoto, K. (2013) Molecular Mechanism of Action of Metformin: Old or New Insights? Diabetologia, 56, 1898-1906. https://doi.org/10.1007/s00125-013-2991-0
Burcelin, R. (2014) The Antidiabetic Gutsy Role of Metformin Uncovered? Gut, 63, 706-707. https://doi.org/10.1136/gutjnl-2013-305370
Chiang, M.-C., Cheng, Y.-C., Chen, S.-J., Yen, C.-H. and Huang, R.-N. (2016) Metformin Activation of AMPK-Dependent Pathways Is Neuroprotective in Human Neural Stem Cells against Amyloid-Beta-Induced Mitochondrial Dysfunction. Experimental Cell Research, 347, 322-331. https://doi.org/10.1016/j.yexcr.2016.08.013
DiTacchio, K. (2011) The Effect of AMPK Activation on Alzheimer’s-Like Symptoms in APP Mice. University of California, San Diego.
Herath, P.M., Cherbuin, N., Eramudugolla, R. and Anstey, K.J. (2016) The Effect of Diabetes Medication on Cognitive Function: Evidence from the PATH through Life Study. BioMed Research International, 2016, Article ID: 7208429
Mostafa, D.K., Ismail, C.A. and Ghareeb, D.A. (2016) Differential Metformin Dose-Dependent Effects on Cognition in Rats: Role of Akt. Psychopharmacology, 233, 2513-2524. https://doi.org/10.1007/s00213-016-4301-2
Hettich, M.M., et al. (2014) The Anti-Diabetic Drug Metformin Reduces BACE1 Protein Level by Interfering with the MID1 Complex. PLoS ONE, 9, e102420. https://doi.org/10.1371/journal.pone.0102420
Alzoubi, K.H., Khabour, O.F., Al-azzam, S.I., Tashtoush, M.H. and Mhaidat, N.M. (2014) Metformin Eased Cognitive Impairment Induced by Chronic L-Methionine Administration: Potential Role of Oxidative Stress. Current Neuropharmacology, 12, 186-192. https://doi.org/10.2174/1570159X11666131120223201
Arafa, N.M., Marie, M.A. and AlAzimi, S.A. (2016) Effect of Canagliflozin and Metformin on Cortical Neurotransmitters in a Diabetic Rat Model. Chemico-Biological Interactions, 258, 79-88. https://doi.org/10.1016/j.cbi.2016.08.016
Abner, E.L., et al. (2016) Diabetes Is Associated with Cerebrovascular but not Alzheimer’s Disease Neuropathology. Alzheimer’s & Dementia, 12, 882-889. https://doi.org/10.1016/j.jalz.2015.12.006
Beeri, M.S., et al. (2005) Type 2 Diabetes Is Negatively Associated with Alzheimer’s Disease Neuropathology. Journals of Gerontology: Series A, Biological Sciences and Medical Sciences, 60, 471-475. https://doi.org/10.1093/gerona/60.4.471
Sonnen, J.A., Larson, E.B. and LBchB, K.B., et al. (2009) Different Patterns of Cerebral Injury in Dementia with or without Diabetes. Archives of Neurology, 66, 315-322. https://doi.org/10.1001/archneurol.2008.579
Mima, Y., et al. (2016) Impact of Metformin on the Severity and Outcomes of Acute Ischemic Stroke in Patients with Type 2 Diabetes Mellitus. Journal of Stroke and Cerebrovascular Diseases, 25, 436-446. https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.10.016
Giannarelli, R., Aragona, M., Coppelli, A. and Del Prato, S. (2003) Reducing Insulin Resistance with Metformin: The Evidence Today. Diabetes & Metabolism, 29, 6S28-35.
Hsu, C.-C., Wahlqvist, M.L., Lee, M.-S. and Tsai, H.-N. (2011) Incidence of Dementia Is Increased in Type 2 Diabetes and Reduced by the Use of Sulfonylureas and Metformin. Journal of Alzheimer’s Disease, 24, 485-493. https://doi.org/10.3233/JAD-2011-101524
Imfeld, P., Bodmer, M., Jick, S.S. and Meier, C.R. (2012) Metformin, Other Antidiabetic Drugs, and Risk of Alzheimer’s Disease: A Population-Based Case-Control Study. Journal of the American Geriatrics Society, 60, 916-921. https://doi.org/10.1111/j.1532-5415.2012.03916.x
Guo, M., et al. (2014) Metformin May Produce Antidepressant Effects through Improvement of Cognitive Function among Depressed Patients with Diabetes Mellitus. Clinical and Experimental Pharmacology and Physiology, 41, 650-656.
McNeilly, A.D., Williamson, R., Balfour, D.J.K., Stewart, C.A. and Sutherland, C. (2012) A High-Fat-Diet-Induced Cognitive Deficit in Rats that Is Not Prevented by Improving Insulin Sensitivity with Metformin. Diabetologia, 55, 3061-3070. https://doi.org/10.1007/s00125-012-2686-y
Qiu, W.Q. and Zhu, H. (2014) Amylin and Its Analogs: A Friend or Foe for the Treatment of Alzheimer’s Disease? Frontiers in Aging Neuroscience, 6, 186. https://doi.org/10.3389/fnagi.2014.00186
Verdile, G., Fuller, S.J. and Martins, R.N. (2015) The Role of Type 2 Diabetes in Neurodegeneration. Neurobiology of Disease, 84, 22-38. https://doi.org/10.1016/j.nbd.2015.04.008
Adler, B.L., et al. (2014) Neuroprotective Effects of the Amylin Analogue Pramlintide on Alzheimer’s Disease Pathogenesis and Cognition. Neurobiology of Aging, 35, 793-801. https://doi.org/10.1016/j.neurobiolaging.2013.10.076